section name header

Pronunciation

tra-BEK-te-din

Classifications

Therapeutic Classification: antineoplastics

Pharmacologic Classification: alkylating agents

Indications

REMS

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: IV administration results in complete bioavailability.

Distribution: Extensively distributed.

Protein Binding: 97%.

Metabolism/Excretion: Primarily metabolized via CYP3A in liver to inactive metabolites. 58% excreted in feces and 6% in urine (primarily as metabolites).

Half-life: 175 hr.

Time/Action Profile

(blood levels)

ROUTEONSETPEAKDURATION
IVunknownunknownunknown

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: peripheral edema, HF, CAPILLARY LEAK SYNDROME.

GI: appetite, constipation, diarrhea, hepatotoxicity, nausea, vomiting.

GU: serum creatinine, fertility, renal failure.

Hemat: anemia, neutropenia, thrombocytopenia.

Local: extravasation.

MS: creatine kinase, arthralgia, myalgia, RHABDOMYOLYSIS.

Neuro: fatigue, headache, insomnia.

Resp: dyspnea.

Interactions

Drug-Drug:

Drug-Natural Products:

Route/Dosage

Hepatic Impairment

Availability

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Yondelis